H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $50 and keeps a Buy rating on the shares. The firm increased assumptions for Tryngolza penetration rates following the Q2 report.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Financial Performance and Strategic Growth Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q2 2025 Results
- Ionis Pharmaceuticals: Strong Financial Performance and Promising Clinical Developments Drive Buy Rating
- Ionis Pharmaceuticals: Strong Performance and Promising Future Drive Buy Rating Upgrade
- Ionis upgraded to Overweight from Equal Weight at Morgan Stanley